Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b.
In human volunteers, single injections of purified polyribophosphate elicited antibodies detectable by passive hemagglutination and by serum bactericidal and opsonizing activities against viable Hemophilus influenzae, type b. All three activities rose by 2 wk to maximal levels, at which they remained for at least 6 months. Doses of 1 mug elicited antibody responses in nearly all recipients; higher doses of the antigen, however, produced larger increases in titer. Booster doses of 1 mug given at 6 months did not further increase the antibody titers. A tuberculin-like response was often observed at the site of injections given intradermally.
D000818:Animals; D000906:Antibodies / Q000032:analysis; D000942:Antigens, Bacterial; D002850:Chromatography, Gel; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control*; D006193:Haemophilus influenzae / Q000276:immunology*; D006386:Hemagglutination Tests; D006801:Humans; D007114:Immunization; D007122:Immunoelectrophoresis; D007271:Injections, Intradermal; D007279:Injections, Subcutaneous; D011135:Polysaccharides, Bacterial; D051381:Rats
D000906:Antibodies; D000942:Antigens, Bacterial; D011135:Polysaccharides, Bacterial